MIF
Macrophage migration inhibitory factor
As of the edition of 20 October 2026, MIF (macrophage migration inhibitory factor, UniProt P14174) has 3 drugs tested at it and 4 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P14174
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 118
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Blood and lymph; Eye; Mouth and teeth; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 27
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Iguratimod | Marketed | Phase 4 | none listed |
| IPG1094 | Active | Phase 2 | none listed |
| Imalumab | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 1 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Takeda | Route A |
The other 3 companies at MIF
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at MIF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.